IVV vs PBE
iShares Core S&P 500 ETF vs Invesco Biotechnology and Genome ETF
Which is better, IVV or PBE?
Large Cap Blend against Small Cap Blend.
IVV has a lower expense ratio. IVV led over 3Y, 5Y and the full window, PBE over 1Y. IVV is less concentrated, with 37.8% of the fund in its ten largest positions against 46.5%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | IVV | PBE |
|---|---|---|
| Expense Ratio | 0.03%Best | 0.58% |
| AUM | $876.4B | $477M |
| Dividend Yield | 1.06% | 1.60% |
| Holdings | 508 | 33 |
| YTD Return | +14.15% | +17.80%Best |
| 1Y Return | +17.31% | +38.55%Best |
| 3Y Return (annualized) | +23.17%Best | +19.52% |
| 5Y Return (annualized) | +13.85%Best | +4.91% |
| Volatility (annualized) | 15.0%Best | 21.2% |
| Max Drawdown | -56.5% | -45.7%Best |
| $10,000 over 5 years | $19,128Best | $12,708 |
| Top 10 Weight | 37.8%Best | 46.5% |
| Fund Family | iShares by BlackRock (US) | Invesco (US) |
| Category | Equity | Equity |
| Style | Large Cap Blend | Small Cap Blend |
| Inception | May 15, 2000 | Jun 23, 2005 |
Volatility and max drawdown are measured over the window both funds cover: Jun 23, 2005 to Sep 21, 2026 (21.2 years).
IVV vs PBE growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 21.2 years both funds cover.
IVV vs PBE Performance
iShares Core S&P 500 ETF (IVV) is an ETF from iShares by BlackRock (US) and Invesco Biotechnology and Genome ETF (PBE) is an ETF from Invesco (US). Over the past year IVV returned +17.31% while PBE returned +38.55%. Year to date, IVV is up 14.15% versus a gain of 17.80% for PBE.
Over three years, IVV compounded at +23.17% per year against +19.52% for PBE; over five years the annualized figures are +13.85% and +4.91% respectively. Across the full 21-year window we track, IVV has the edge at +9.60% annualized vs +9.34%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
PBE has been the more volatile fund, with annualized monthly volatility of 21.2% compared with 15.0% for IVV. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -56.5% for IVV and -45.7% for PBE. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.67. They move together some of the time, and apart the rest.
Fees and Cost Over Time
IVV charges 0.03% per year while PBE charges 0.58%. On a $10,000 position that is $3 vs $58 annually, a gap of $55 per year that compounds over a long holding period. On income, IVV currently yields 1.06% against 1.60% for PBE.
Holdings Overlap
1.1% of IVV's money is in holdings PBE also owns. 31.7% of PBE's money is in holdings IVV also owns.
The two portfolios partly overlap.
7 positions in common, counted across the 490 positions we hold weights for in IVV and 31 in PBE, against full books of 508 and 33.
What only one of them owns
Our book lists 22 positions for PBE that do not appear in our book for IVV (60.6% of the fund), and 475 for IVV that do not appear in PBE (97.6%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in IVV | Weight in PBE | Difference |
|---|---|---|---|
| AMGNAmgen Inc. | 0.35% | 5.42% | 5.07% |
| VRTXNvaesrtex Pharmaceuticals Inc | 0.21% | 5.28% | 5.07% |
| REGNRegeneron Pharmaceuticals, Inc. | 0.12% | 5.30% | 5.18% |
| GILDGilead Sciences | 0.27% | 4.61% | 4.34% |
| BIIBBiogen Inc. Com | 0.05% | 4.73% | 4.68% |
| TECHBio-Techne Corp | 0.02% | 3.47% | 3.45% |
| INCYIncyte Corp. | 0.03% | 2.92% | 2.89% |
31.7% of PBE is already inside IVV.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, IVV or PBE?
IVV has an expense ratio of 0.03% while PBE charges 0.58%. IVV is the cheaper option, by $55 a year on a $10,000 investment.
Which performed better, IVV or PBE?
Over the past year IVV returned +17.31% vs +38.55% for PBE, so PBE leads on 1-year performance. Over the longest common window we track (21 years), IVV annualized +9.60% vs +9.34% for PBE. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, IVV or PBE?
PBE has been the more volatile fund at 21.2% annualized versus 15.0% for IVV. Worst drawdown: IVV -56.5% vs PBE -45.7%.
Should I hold both IVV and PBE?
IVV and PBE have a monthly-return correlation of 0.67, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between IVV and PBE?
31.7% of PBE's money is in holdings IVV also owns. 31.7% of PBE's is in holdings IVV also owns. They hold 7 positions in common, counted across the 490 positions we hold weights for in IVV and 31 in PBE.
Which pays a higher dividend, IVV or PBE?
IVV yields 1.06% while PBE yields 1.60%, so PBE currently pays the higher dividend yield.
Is PBE better than IVV?
IVV has a lower expense ratio. IVV led over 3Y, 5Y and the full window, PBE over 1Y. IVV is less concentrated, with 37.8% of the fund in its ten largest positions against 46.5%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.